Eli Lilly (LLY) Up 6% in a Month – Can It Climb Higher?

Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level. On June 25, Leerink analyst David Risinger raised the price target on the stock, reinforcing bullish sentiment.

Rating Change

Analyst David Risinger raised the price target for Eli Lilly while maintaining a positive rating. The exact new target was not disclosed, but the revision reflects an optimistic outlook.

Analyst Rationale

Risinger cites the strength of Eli Lilly's diabetes and obesity drugs, particularly Mounjaro and Zepbound, as key growth drivers. The company's promising pipeline also supports the positive view.

Context

The upgrade comes as LLY shares have performed strongly, gaining 6% over the past month. Other analysts remain bullish, with a consensus price target implying 13.6% upside.

What to Make of It

Eli Lilly remains a focus for investors due to its robust metabolic drug portfolio. The Leerink upgrade supports the bullish case, but investors should monitor market and competitive developments.